国投证券股份有限公司 关于深圳微芯生物科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）作为深圳 微芯生物科技股份有限公司（以下简称"微芯生物"或"公司"）首次公开发行 股票并在科创板上市项目和向不特定对象发行可转换公司债券项目的保荐机构， 根据《证券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号—上市公 司募集资金管理和使用的监管要求（2022 年修订）》、《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》、《上海证券交易所科创板股票 上市规则》、《深圳微芯生物科技股份有限公司募集资金管理制度》等有关规定， 对公司 2024 年度募集资金存放与使用情况进行了认真、审慎的核查，并发表意 见如下： 一、募集资金基本情况 （一）实际募集资金情况 1. 2019 年首次公开发行股票 根据中国证券监督管理委员会 2019 年 7 月 17 日出具的《关于同意深圳微芯 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1299 号），公司首次公开发行人民币普通股（A 股）50,000,000 股 ...

上海 SHANGHAI 北京 BEIJING SHANGHAI Vin Chena Road Middle 上海市通力律师事务所关于深圳微芯生物科技股份有限公司 2021 年股票增值权激励计划作废部分股票增值权相关事宜之 法律意见书 致:深圳微芯生物科技股份有限公司 敬启者: 上海市通力律师事务所(以下简称"本所")受深圳微芯生物科技股份有限公司(以下简 称"微芯生物"或"公司")委托,指派本所陈军律师、郭珣律师(以下合称"本所律师") 作为公司特聘专项法律顾问,根据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会(以下简 称"中国证监会")发布的《上市公司股权激励管理办法》(以下简称"《管理办法》")等 法律、行政法规以及其他规范性文件(以下简称"法律、法规以及规范性文件")、《深圳微 芯生物科技股份有限公司章程》(以下简称"《公司章程》")、《深圳微芯生物科技股份有 限公司 2021 年股票增值权激励计划》(以下简称"《股票增值权激励计划》")的有关规定, 就公司 2021 年股票增值权激励计划(以下简称"本次股票增值权激励计 ...

关于深圳微芯生物科技股份有限公司 2024 年度营业收入扣除情况的专项说明 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 深圳微芯生物科技股份有限公司董事会： 我们接受委托，按照中国注册会计师审计准则审计了深圳微芯生物科技股份有限公司 (以 下简称"微芯生物") 2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负 债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益 变动表以及相关财务报表附注，并于 2025 年 4 ...

深圳微芯生物科技股份有限公司 2024 年度内部控制审计报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 内部控制审计报告 毕马威华振审字第 2512727 号 深圳微芯生物科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了深圳 微芯生物科技股份有限公司 (以下简称"贵公司") 2024 年 12 月 31 日的财务报告内部控制的 有效性。 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 三、内部控制的固有局限性 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内 ...

对深圳微芯生物科技股份有限公司募集资金 2024 年度存放与实际使用情况专项报告的鉴证报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 对深圳微芯生物科技股份有限公司募集资金 2024 年度存放与实际使用情况专项报告的鉴证报告 毕马威华振专字第 2502892 号 深圳微芯生物科技股份有限公司董事会： 我们接受委托，对后附的深圳微芯生物科技股份有限公司 (以下简称"贵公司") 募集资金 2024 年度存放与实际使用情况的专项报告 (以下简称"专项报告") 执行了合理保证的鉴证业 务 ...

国投证券股份有限公司 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）作为深圳 微芯生物科技股份有限公司（以下简称"微芯生物"或"公司"）首次公开发行 股票并在科创板上市项目和向不特定对象发行可转换公司债券项目的保荐机构， 根据《证券发行上市保荐业务管理办法》、《上市公司监管指引第 2 号—上市公司 募集资金管理和使用的监管要求（2022 年修订）》、《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》、《上海证券交易所科创板股票上市规 则》、《深圳微芯生物科技股份有限公司募集资金管理制度》等有关规定，对公司 本次使用剩余超募资金永久性补充流动资金进行了认真、审慎的核查，并发表意 见如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意深圳微芯生物科技股份有限 司首次公开发行股票注册的批复》（证监许可〔2019〕1299 号），公司首次向社会 公众公开发行人民币普通股(A 股)5000.00 万股，每股面值人民币 1 元，每股发 行价格为人民币 20.43 元，募集资金总额为人民币 102,150.00 万元，扣除与募集 资金相关的发行费用共计人民币 7,631.1 ...

深圳微芯生物科技股份有限公司 2024 年度财务审计报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2512603 号 深圳微芯生物科技股份有限公司全体股东： 一、审计意见 我们审计了后附的深圳微芯生物科技股份有限公司 (以下简称"微芯生物") 财务报表，包 括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并 及母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报 ...

Financial Performance - The company reported a net profit attributable to shareholders of -114.57 million yuan for the year 2024, with the parent company achieving a net profit of -88.42 million yuan[11]. - The company has decided not to distribute cash dividends, issue bonus shares, or increase capital reserves for the year 2024, despite having positive undistributed profits[11]. - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a 15% increase year-over-year[20]. - The company's operating revenue for 2024 reached ¥657,949,379.86, representing a 25.63% increase compared to ¥523,710,192.86 in 2023[28]. - The net profit attributable to shareholders was -¥114,570,600.33 in 2024, a decrease of 228.96% from ¥88,838,537.36 in 2023[28]. - The net cash flow from operating activities improved by 148.40%, totaling ¥76,128,277.31, compared to -¥157,273,634.35 in the previous year[28]. - The company's total assets increased by 1.49% to ¥3,250,899,058.18 at the end of 2024, up from ¥3,203,249,429.12 in 2023[28]. - The basic earnings per share for 2024 was -¥0.2808, a decline of 229.04% from ¥0.2176 in 2023[29]. - The company reported a significant increase in sales of its products, particularly Xidabena and Siglitazone, contributing to the rise in operating revenue[30]. - The company achieved total revenue of 657.9494 million yuan, a year-on-year increase of 25.63%, primarily due to significant sales growth of its products, including Xidabena (爱谱沙®) and Siglitazone (双洛平®) [40]. Research and Development - Research and development expenses increased by 20%, totaling 200 million RMB in 2023, focusing on innovative drug development[20]. - The company's R&D investment accounted for 51.49% of total revenue, reflecting ongoing efforts to enhance R&D efficiency and achieve significant progress in key projects [40]. - The company has developed two innovative drugs that are globally marketed across multiple indications in oncology, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral fields [39]. - The company is advancing its AI-assisted drug discovery platform, integrating various AI technologies to enhance early-stage R&D projects [41]. - The company is dynamically adjusting its pipeline layout based on scientific mechanisms, clinical evidence, and market changes, focusing on unmet clinical needs [41]. - The company has multiple R&D projects in oncology, metabolic diseases, autoimmune diseases, CNS diseases, and antiviral fields, with candidates like CS1011, CS08399, and CS25141 showing potential as best-in-class drugs[72]. - The company has filed 744 invention patent applications globally and received 222 patent grants, covering multiple regions including North America, Southeast Asia, and Europe[123]. Product Development and Market Expansion - The product Sigleptin (双洛平®) has seen rapid growth in the healthcare market, with the company reclaiming marketing rights in 19 provinces, aiming to establish it as a foundational drug for metabolic disease treatment[4]. - The company is focusing on expanding the application of Sidabenad (爱谱沙®) in treating diffuse large B-cell lymphoma, with expectations for strong commercial performance in 2025[5]. - New product launches are expected to contribute an additional 300 million RMB in revenue in 2024[20]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[20]. - The company is actively exploring external cooperation opportunities to accelerate the development of its innovative drugs, including potential licensing agreements for its products[51]. - The company has established a commercial team focused on oncology and metabolic diseases, enhancing its market presence[52]. - The company is preparing for multinational multi-center clinical trials, laying a solid foundation for upcoming research initiatives[188]. Clinical Trials and Approvals - The CAPability-01 study for colorectal cancer has gained significant attention and has been included in the "breakthrough therapy" category by the drug review center, with ongoing Phase III clinical trials[5]. - The clinical trial for Xidabena in combination with R-CHOP for treating double-expressing diffuse large B-cell lymphoma is expected to be approved for market launch on April 24, 2024[42]. - The clinical trial for Siglitazone in combination with metformin for new indications in type 2 diabetes was approved for market launch on July 16, 2024[43]. - The company has completed over 90% enrollment in the Phase III clinical trial of Xioroni for treating platinum-resistant recurrent ovarian cancer[44]. - The company is preparing for the I phase clinical trial of CS231295, a selective Aurora B inhibitor, and has received approval for several other early-stage projects [45]. - The company has received approval for several clinical trial applications, including for Ibrutinib combined with Sintilimab for advanced microsatellite-stable colorectal cancer[167]. Operational Efficiency and Management - The company has successfully completed a leadership transition and enhanced its management structure, appointing new executives to improve operational efficiency[6]. - The company emphasizes a commitment to clinical demand-driven innovation and plans to accelerate clinical development and internationalization efforts[6]. - The company is committed to addressing various operational risks and has outlined measures to mitigate these risks in its annual report[8]. - The company has successfully completed the restructuring of its board and management team, improving governance and operational compliance[46]. - The company is committed to deepening its digital transformation strategy, expanding the application of digital learning to support employee growth[47]. - The company has established a systematic risk management mechanism to reduce operational risks and enhance the quality of information disclosure[196]. Market Trends and Industry Insights - The global biotech financing environment remains weak, with only 32 biotech companies going public in 2024, similar to 2022-2023 levels, and significantly lower than 2019-2021[80]. - In 2023, the M&A scale for multinational pharmaceutical companies reached a historical high of approximately $160 billion, although it is expected to decline in 2024[81]. - The Chinese pharmaceutical market is projected to reach approximately $197 billion by 2025, accounting for about 10% of the global market[83]. - The company is actively pursuing international market expansion through collaborations and patent licensing, ensuring compliance with international standards in clinical trials[121]. Sustainability and Corporate Governance - The company has received multiple awards in the ESG field, including the "Most Socially Responsible Award" and the "Outstanding Governance Construction Award" in 2024, reflecting external recognition of its ESG practices[54]. - The company is committed to sustainable development and has integrated ESG principles into its corporate strategy, aiming for long-term, stable, and sustainable growth[54]. - The company adheres to compliance and sustainable development principles, optimizing its corporate governance structure and ensuring transparency in operations[196].

Financial Performance - The company's revenue for Q1 2025 was CNY 162.26 million, representing a 24.24% increase compared to CNY 130.60 million in the same period last year[2]. - The net profit attributable to shareholders was a loss of CNY 19.15 million, slightly worsening from a loss of CNY 18.30 million year-over-year, reflecting a 4.64% increase in losses[2]. - The diluted earnings per share for the quarter was CNY -0.0470, compared to CNY -0.0448 in the same period last year, reflecting a 4.91% increase in losses per share[3]. - Net loss for Q1 2025 was ¥19.15 million, compared to a net loss of ¥18.30 million in Q1 2024, reflecting a 4.6% increase in losses[14]. - Other comprehensive income after tax for Q1 2025 was -¥81.68 million, contrasting with a positive amount of ¥112.70 million in Q1 2024[14]. Cash Flow - The net cash flow from operating activities decreased by 43.60%, down to CNY 19.98 million from CNY 35.43 million in the previous year, primarily due to increased material purchases and operating expenses[5]. - Cash flow from operating activities for Q1 2025 was ¥19.98 million, down 43.5% from ¥35.43 million in Q1 2024[16]. - Cash flow from investing activities showed a net outflow of ¥57.11 million in Q1 2025, compared to a net inflow of ¥25.47 million in Q1 2024[16]. - Cash flow from financing activities generated a net inflow of ¥58.56 million in Q1 2025, an increase from ¥33.41 million in Q1 2024[17]. - The ending cash and cash equivalents balance for Q1 2025 was ¥243.83 million, down from ¥361.16 million at the end of Q1 2024[17]. Research and Development - Research and development expenses totaled CNY 73.05 million, accounting for 45.02% of revenue, down from 61.41% in the previous year, indicating a decrease of 16.39 percentage points[3]. - Research and development expenses for Q1 2025 were ¥52.91 million, slightly up from ¥52.50 million in Q1 2024[13]. Assets and Liabilities - Total assets increased by 1.87% to CNY 3.31 billion from CNY 3.25 billion at the end of the previous year[3]. - The company's total current assets reached RMB 1,134,827,622.72, up from RMB 1,083,471,551.64, indicating an increase of about 4.71%[10]. - The company's inventory increased to RMB 50,753,968.26 from RMB 40,843,656.94, representing a growth of around 24.5%[10]. - Total liabilities rose to RMB 1,749,840,730.61 from RMB 1,669,800,309.41, marking an increase of about 4.79%[11]. - The company's total equity decreased to RMB 1,561,862,397.76 from RMB 1,581,098,748.77, a decline of approximately 1.22%[11]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,684[6]. - The largest shareholder, Boao Biological Group Co., Ltd., holds 34,705,162 shares, representing 8.51% of the total shares[7]. Government Subsidies - The company received government subsidies amounting to CNY 5.60 million, which positively impacted its financial performance[4].

深圳微芯生物科技股份有限公司 2024 年度独立董事述职报告 2024 年，作为深圳微芯生物科技股份有限公司（以下简称"公司"）的独立 董事，根据《公司法》《证券法》《上海证券交易所科创板股票上市规则》等法律 法规及《深圳微芯生物科技股份有限公司章程》（以下简称"《公司章程》"）、《深 圳微芯生物科技股份有限公司独立董事工作制度》（以下简称"《独立董事工作制 度》"）等规定，在 2024 年度工作中诚实、勤勉、独立地履行职责，积极出席相 关会议，认真审议董事会各项议案，对公司重要事项发表了独立意见，有效维护 公司全体股东特别是中小股东的合法权益。现将 2024 年度履职情况汇报如下： 一、公司独立董事的基本情况 （一）个人履历 黄民，男，研究生学历，药理学博士学位，二级教授。黄民先生为国家药典 委员、中国药理学会药物代谢专业委员会副主任委员、广东省科协常务委员、广 东省审评认证技术协会会长。黄民先生于 1983 年 6 月参加工作，曾先后担任中 山医科大学临床药理教研室讲师、副教授、中山大学药学院常务副院长、院长等 职务，现任中山大学临床药理研究所教授、所长。黄民先生在药学领域教学、科 研、科技开发等方面具有 ...